By Gina Shaw
Providers, payors and patients will have to wait a little longer for highly anticipated outcomes data on the new cholesterol-lowering proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Kristen Davis, a spokeswoman for Amgen, the developer of evolocumab (Repatha), confirmed to SPC on June 23 that top-line results from the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) trial will likely not be released until